Providing additional options for CRISPR-based research
The last thing you should have to worry about in product development is choosing the right CRISPR nuclease. You need licensing access to any field or application you wish to work on.
Inscripta developed and released the MAD7 nuclease to the global research community in 2017 under a broad technology access program to democratize access to CRISPR and promote its widespread adoption in both academic and commercial settings.
Inscripta will soon offer a portfolio of MADzyme™ nucleases under an expanded, non-exclusive licensing program, including several MAD7 variants with improved properties such as expanded PAM sites, and higher fidelity. Please contact us below to learn more.
Coming Soon! Wild type MAD7 protein will be available to purchase off-the-shelf from our trusted partners at Aldevron. See the press release.